122 related articles for article (PubMed ID: 35092971)
1. [The application value of plasma heterogeneous nuclear ribonucleoprotein A2/B1, Aβ
Zhang YY; Xin X; Yang CY; Wang XY; Xia T; Wang HY
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(5):321-325. PubMed ID: 35092971
[No Abstract] [Full Text] [Related]
2. [The predictive value of melanin-concentrating hormone combined with other related biomarkers in cerebrospinal fluid in preoperative cognitive dysfunction of elderly patients].
Gao Y; Zhao YJ; Li Y; Song JN; Zhang XZ; Sun Y; Yu M; Zhou Q
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(35):2772-2777. PubMed ID: 37723051
[No Abstract] [Full Text] [Related]
3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
5. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
6. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
Tieu MV; Choi SH; Le HTN; Cho S
Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
[TBL] [Abstract][Full Text] [Related]
7. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J
J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
9. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
10. Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer's disease.
Mirandez RM; Aprahamian I; Talib LL; Forlenza OV; Radanovic M
Int Psychogeriatr; 2017 Jun; 29(6):949-958. PubMed ID: 28179036
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
[TBL] [Abstract][Full Text] [Related]
12. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
13. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
He B; Wang L; Xu B; Zhang Y;
Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
[TBL] [Abstract][Full Text] [Related]
14. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
15. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
Vanderstichele H; De Meyer G; Andreasen N; Kostanjevecki V; Wallin A; Olsson A; Blennow K; Vanmechelen E
Clin Chem; 2005 Sep; 51(9):1650-60. PubMed ID: 16020497
[TBL] [Abstract][Full Text] [Related]
16. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.
Verberk IMW; Slot RE; Verfaillie SCJ; Heijst H; Prins ND; van Berckel BNM; Scheltens P; Teunissen CE; van der Flier WM
Ann Neurol; 2018 Nov; 84(5):648-658. PubMed ID: 30196548
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
[TBL] [Abstract][Full Text] [Related]
19. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous nuclear ribonucleoprotein B1 as a new marker of early detection for human lung cancers.
Sueoka E; Goto Y; Sueoka N; Kai Y; Kozu T; Fujiki H
Cancer Res; 1999 Apr; 59(7):1404-7. PubMed ID: 10197602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
